Venture Life Group PLC (LON:VLG)‘s stock had its “buy” rating reaffirmed by analysts at Panmure Gordon in a research note issued on Monday. They presently have a GBX 128 ($1.58) target price on the stock. Panmure Gordon’s price objective points to a potential upside of 128.57% from the company’s current price.

Separately, Beaufort Securities restated a “speculative buy” rating on shares of Venture Life Group PLC in a report on Thursday, September 22nd.

Venture Life Group PLC (LON:VLG) traded down 2.73% during trading on Monday, hitting GBX 53.50. 12,577 shares of the company’s stock were exchanged. The firm’s market cap is GBX 19.71 million. The company’s 50-day moving average price is GBX 51.68 and its 200 day moving average price is GBX 55.94. Venture Life Group PLC has a 12-month low of GBX 43.00 and a 12-month high of GBX 81.92.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

About Venture Life Group PLC

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related companies with's FREE daily email newsletter.